triptorelin + goserelin + leuprorelin

This is a combination of three gonadotropin-releasing hormone (GnRH) agonists—triptorelin, goserelin, and leuprorelin. Each of these agents is a synthetic decapeptide analog of endogenous GnRH (also known as luteinizing hormone-releasing hormone, LHRH). They act by initially stimulating and then downregulating the pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to suppression of gonadal steroidogenesis. This results in reduced levels of testosterone in males and estrogen in females. These drugs are primarily used for androgen deprivation therapy in advanced prostate cancer, but also have indications for breast cancer and other sex-hormone-dependent conditions[1][2][3][6]. There is no evidence that this specific triple combination is marketed or clinically used as a fixed-dose product; rather, each agent is typically used individually.